合作類型：技術(shù)     行業(yè)類別: 診斷       過期時間：2016年10月24日   

法國癌癥中心已鑒別出了一種新的蛋白質(zhì)生物標記物，主要針對乳腺癌和結(jié)腸癌。該新的生物標記物可較為準確的診斷和預(yù)測這兩種癌癥。目前正在尋找許可證協(xié)議和技術(shù)合作。

英文原文：A french cancer center has identified a new protein biomarker, highly specific for breast and colon cancer. This new biomarker allows for a more accurate diagnostic and prognostic for both illness. Industrial partners are sought for licence agreement or technical cooperation. The use of prognosis biomarkers is verry important in helping clinicians in their therapeutic decision. First generation biomarkers currently in use for diagnosis / prognosis of breast and colon cancer often lead to false-positive results. New generation biomarkers currently under development will help with clearer and accurate prognosis. The laboratory has identified a new protein biomarker, highly specific for breast and colon cancer, which more accurately helps predicts the risk for cancer to relapse and/or to develop metastases. The analysis of this marker expression by TMA (Tissue MicroArrays) immunohistochemistry on breast and colon cancer samples, has demonstrated that colorectal tumors showing more than 50% positively-stained cells or breast tumors showing less than 50% positively-stained cells are related to high risks of relapse, either local or metastatic. Partners for technical cooperation agreement are sought in order to improve the biomarker results. The addition of a single protein marker to predict metastatic progression of good prognosis cancers is: - more accurate than the previous versions of biomarkers - Simpler & faster to perform, - Less expensive Thickness control of the cladding layer Rapid deposition Simple process Reduced cost No crucible (no contamination) Analysis of TMA breast & colorectal cancer samples with RT-QPCR and immunohistochemistry (cancer samples considered of good prognosis using classical markers – Gleason 1 to 4 for colon cancer and SBR 1 to 3 for breast cancer).